Impact of bisphosphonate compliance on the risk of osteoporotic fracture in France
Limited information is available on the impact of bisphosphonate compliance levels on fracture risk in osteoporosis patients in France. The results of this nested case-control, retrospective study suggest that fracture risk did not significantly change with bisphosphonate compliance levels, except for highly compliant patients.
This was the first study conducted in France to evaluate the impact of compliance levels for bisphosphonates, the most frequently prescribed first-line anti-osteoporotic treatment, on fracture risk.
This retrospective nested case-control study included patients ≥ 50 years old, who were recorded in a random sample of French claims data, did not die between 2006 and 2013, and received ≥ 1 reimbursement for anti-osteoporotic treatment between 2007 and 2013. Cases (patients hospitalised for osteoporosis-related fractures) were matched to 1–3 controls (patients hospitalised for other reasons). Patients hospitalised for fractures within 12 months preceding the first delivery of anti-osteoporotic treatment or during the first 24 months of follow-up were excluded. Bisphosphonate compliance during the 24 months preceding hospitalisation was calculated by the Continuous measure of Medication Acquisition version 7 (CMA7). We evaluated the impact of bisphosphonate compliance (CMA7 ≥ 80%) and very good compliance levels (CMA7 > 90%) on fracture risk.
In the main analysis, the mean CMA7 values during the 24 months preceding hospitalisation were 48.4% for the 434 cases and 51.3% for the 1123 age-matched controls. An adjusted conditional logistic regression showed no significant impact (odds ratio: 0.851 [95% confidence interval: 0.668, 1.084]) of bisphosphonate compliance on fracture occurrence. In the sensitivity analysis, including one randomly selected control per case and only controls with CMA7 values > 90%, occurrence of fractures was lower (odds ratio: 0.741 [95% confidence interval: 0.608, 0.903]) among the 119 controls.
In conclusion, this study suggested that very high levels of compliance with bisphosphonates are necessary to induce significant decreases in fracture risk.
KeywordsOsteoporosis Treatment Epidemiology Outcomes research
Bone mineral density
Continuous measure of Medication Acquisition version 7
Chronic obstructive pulmonary disease
Echantillon généraliste de bénéficiaires
International classification of diseases, 10th edition
Medication possession rate
Nonsteroidal anti-inflammatory drugs
We thank the French National Health Service (Caisse Nationale de l’Assurance Maladie des Travailleurs Salariés) and the Institute of Health Data (Institut des Données de Santé) for providing data. The authors thank Claire Verbelen (XPE Pharma & Science, Wavre, Belgium) for professional medical writing support.
All authors critically reviewed the manuscript. E.V.G. obtained funding. E.V.G. and M.B. provided supervision, conceived and designed the study, interpreted the data, and drafted the manuscript. M.G. performed the statistical analysis. B.C. and C.B.C. conceived and designed the study and interpreted the data. L.L. contributed to study design and interpretation of data. M.B. is the guarantor of the study.
This study was funded by a non-conditional grant from MSD France.
Compliance with ethical standards
Conflicts of interest
Ethics approval and consent to participate
This observational study was conducted on anonymised claims data (EGB), and the National Informatics and Liberty Committee has delivered an overall authorisation to use EGB data for research purposes. This study was performed after approval by the Institute of Health Data (Institut des Données de Santé, approval 63, June 11, 2013).
Consent to publish
- 1.Vijayakumar R, Büsselberg D (2016) Osteoporosis: An under-recognized public health problem. Journal of Local and Global Health ScienceGoogle Scholar
- 3.Briot K, Cortet B, Thomas T, Audran M, Blain H, Breuil V, Chapuis L, Chapurlat R, Fardellone P, Feron JM, Gauvain JB, Guggenbuhl P, Kolta S, Lespessailles E, Letombe B, Marcelli C, Orcel P, Seret P, Trémollières F, Roux C (2012) 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. Joint Bone Spine 79(3):304–313CrossRefGoogle Scholar
- 9.Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18):1809–1822CrossRefGoogle Scholar
- 11.Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V et al (2008) Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 1Google Scholar
- 12.Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V et al (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 1Google Scholar
- 13.Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V et al (2008) Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 1Google Scholar
- 14.Ferguson S, Feudjo Tepie M, Taylor A, Roddam A, Critchlow C, Iqbal M, Spangler L, Bayly J (2016) The impact of persistence with bisphosphonates on health resource utilization and fracture risk in the UK: a study of patient records from the UK clinical practice research datalink. J Eval Clin Pract 22(1):31–39CrossRefGoogle Scholar
- 35.Reginster JY, Felsenberg D, Boonen S, Diez-Perez A, Rizzoli R, Brandi ML, Spector TD, Brixen K, Goemaere S, Cormier C, Balogh A, Delmas PD, Meunier PJ (2008) Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum 58(6):1687–1695CrossRefGoogle Scholar
- 37.Sweeney J, Patterson CC, Menzies-Gow A, Niven RM, Mansur AH, Bucknall C, Chaudhuri R, Price D, Brightling CE, Heaney LG (2016) Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the optimum patient care research database and the British thoracic difficult asthma registry. Thorax 71(4):339–346CrossRefGoogle Scholar